More than ever, clinicians need regularly updated reviews given the continuously increasing
amount of new information regarding innovative cervical cancer prevention methods. A …

Based on scientific data showing that HPV testing provides better protection against cervical
precancer and cancer than cytology, in 2011 the Dutch Health Council advised the Minister …

High‐risk human papillomavirus (hrHPV) testing has a higher sensitivity but lower specificity
than cytology for detection of high‐grade intraepithelial neoplasia (CIN). To avoid over …

Background Controversy remains over whether high-risk human papillomavirus (HPV) DNA
testing should be used as a primary screen for cervical cancer. The aims of our study were to …

Background: Some countries have implemented stand-alone human papillomavirus (HPV)
testing while others consider cotesting for cervical cancer screening. We compared both …

Introduction: High-risk human papillomavirus (hrHPV) testing is expected to replace cytology
as primary screening method for cervical cancer screening in an increasing number of …

Objective To determine the trade-off between the sensitivity and the specificity for high grade
cervical intraepithelial neoplasia at hybrid capture 2 cut-off values above the standard≥ 1 …

Cervical screening programs for detecting cancer and precancer have dramatically reduced
the incidence and mortality rates of cervical cancer since the 1960s. The efficacy of the …

OBJECTIVES: We compared the screening performance of conventional Pap cytology and
two human papillomavirus (HPV) DNA assays, the original Hybrid Capture 2 (HC2) and an …

Human Papillomavirus (HPV) testing has been extensively studied in randomized controlled
trials of primary cervical screening. Based on encouraging results concerning its high …